Merck
Merck and Daiichi Sankyo’s ADC Pact Hits Regulatory Setback in FDA Rejection
Merck, Daiichi Sankyo, Antibody-Drug Conjugate (ADC), Patritumab Deruxtecan, FDA Rejection, Regulatory Setback, HER3 Protein, Non-Small Cell Lung Cancer (NSCLC)
FDA Rejects Merck-Daiichi Sankyo’s Lung Cancer Drug, Approves New Treatments for COPD and Lymphoma
FDA, Merck, Daiichi Sankyo, NSCLC, COPD, Lymphoma, Patritumab Deruxtecan, Ensifentrine, Epkinly
FDA Rejects Merck-Daiichi’s HER3-Targeted ADC Due to Manufacturing Issues
FDA, Merck, Daiichi Sankyo, HER3-targeted ADC, patritumab deruxtecan, manufacturing concerns, lung cancer treatment
Merck’s Capvaxive: FDA Approves First Pneumococcal Vaccine Designed for Adults
Merck, Capvaxive, FDA Approval, Pneumococcal Vaccine, Adults, Pneumonia, Invasive Pneumococcal Disease
Moderna and Merck’s Cancer Vaccine Shows Promising Results in Combination with Keytruda
Moderna, Merck, Cancer Vaccine, Keytruda, Melanoma, mRNA Technology, ASCO, FDA, Rare Disease, START Pilot Program
Blackstone Invests $300M in Uniquity Bio to Unleash Merck Drug’s Inflammation & Immunology Potential
Blackstone, Uniquity Bio, Merck, Inflammation & Immunology, Investment, Drug Development, Biotechnology
Merck Pauses Phase 3 TIGIT Trial Due to Immune-Mediated Adverse Events
Merck, Phase 3 Trial, TIGIT, Immune-mediated Adverse Events, Discontinuations
Evaluation of Keytruda Combined with Chemotherapy as Post-Surgical Treatment in Newly Diagnosed Endometrial Cancer Shows Limited Efficacy
Keytruda, Merck, endometrial cancer, post-surgical therapy, newly diagnosed, chemotherapy, clinical trial, limited efficacy.
Pharma Executives of BMS, J&J, and Merck Confronted in Senate Hearing on Sky-High Drug Prices
United States, Prices, CEOs, Country, Johnson and Johnson, R&D, Merck